Hope for thousands of MS patients as ‘life-changing’ drug now on NHS in England

• Fampridine is now available on the NHS in England for eligible MS patients, potentially benefiting up to 5,000 individuals with mobility difficulties
• The drug works by enhancing nerve signal transmission, offering clinically meaningful improvements in walking ability and functional mobility
• GPs and neurologists should identify eligible MS patients with gait impairment and consider referral for fampridine initiation as part of optimised symptom management

Fampridine boosts nerve signals to make it easier to walk, with up to 5,000 eligible.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.